World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 2
Page: 758-775

REGULATORY FRAMEWORKS FOR DECENTRALIZED CLINICAL TRIALS: A COMPARATIVE ANALYSIS OF FDA AND EMA GUIDELINES

Namrata Tatineni[1*]

Masters in Regulatory Affairs, Northeastern University, Boston, USA.

Article Received: 28 February 2025 | | ***Article Revised: 17 March 2025*** | | ***Article Accepted: 08 April 2025***

***Corresponding Author: Namrata Tatineni**
Masters in Regulatory Affairs, Northeastern University, Boston, USA.
DOI: https://doi.org/10.5281/zenodo.15274465

How to cite this Article: Namrata Tatineni (2025). REGULATORY FRAMEWORKS FOR DECENTRALIZED CLINICAL TRIALS: A COMPARATIVE ANALYSIS OF FDA AND EMA GUIDELINES. World Journal of Pharmaceutical Science and Research, 4(2), 758-775. https://doi.org/10.5281/zenodo.15274465

ABSTRACT

Decentralized clinical trials (DCTs) have taken the landscape of clinical research significantly further by exploiting digital technologies, remote monitoring, and telemedicine for patient involvement and data-pulling. However, the governing regulatory frameworks that exist for DCTs vary from region to region, with the U.S. Food and Drug Administration and the European Medicines Agency establishing different sets of guidelines to ensure patient safety, data integrity, and compliance. This review serves to provide a comparative analysis of the regulations set by the FDA and EMA when it comes to DCTs in the following subject areas: remote patient monitoring, eConsent, data protection (HIPAA vs. GDPR), and the artificial intelligence role in overseeing the trial activity. Significant differences, therefore, would also include regulatory flexibility, ethics committee involvement, and data security requirements.

KEYWORDS: Decentralized Clinical Trials (DCTs), FDA Guidelines, EMA Guidelines, Remote Patient Monitoring, eConsent, Data Protection, HIPAA, GDPR, Artificial Intelligence, Regulatory Compliance.

INTRODUCTION

Decentralized Clinical Trials (DCTs) represent shift from the traditional models of clinical trials that are conducted within clinical sites. Rather, these trials use technology and remote monitoring to bring the clinical trial process to the patients' homes or into their local healthcare facilities. All modalities include adaptation for flexible data collection, participant engagement, and patient recruitment, or any combination of them. Some telemedicine applications and mobile apps are used in conjunction with wearable devices, without parting from their role in digital technology, for remote healthcare monitoring, virtual consultations, and even delivery of investigational products to the homes of participants.

Currently, this model is gaining quite a favorable trend for adopting patient-centered, efficient trial designs to minimize burdens on patients and broaden clinical access to trials-the case further highlighted by the need created by the COVID-19 pandemic. Such models will also look at geographical barriers and mobility issues, while making clinical trials more inclusive and accessible.[1,2]

Key Characteristics of DCTs

1. **Remote Participation** – Patients register, consent as well as remotely participate in trials, not requiring them to go to any of the central study sites.
2. **Digital Health Technologies** – Wearable Sensors, Mobile Applications, Telemedicine, and Electronic patient-reported outcomes (ePROs) that collect real-time data.
3. **Direct-to-Patient Drug Delivery** – Medications and Investigational products may be sent directly to patients than dispensed at a health facility or trial site.
4. **Virtual Patient Monitoring** – Connected devices and telehealth consultations allow remote monitoring of health data of patients.
5. **Flexible Study Designs** – Combining remote interaction formats with some visits to site is an example of hybrid DCT study designs or models.
6. **Broader Patient Reach** – DCTs take away geographical barriers and increase diversity in patient recruitment - especially among the underrepresented population.
7. **Electronic Informed Consent (eConsent)** – Digital consent platforms ensure participants have understood what is involved in a clinical trial without stepping foot in their physical sites.
8. **Real-World Data Integration** – Trial data are supplemented with data from electronic health records (EHRs) and digital platform devices to lead to enhanced real-world evidence generation.[3,4,5]

EVOLUTION AND GROWTH OF DCTS IN CLINICAL RESEARCH

Early Beginnings

DCTs came into being largely from the growing acceptance of digital health technologies and telemedicine in the research setting. Initially, trials added remote elements such as electronic data capture (EDC) and ePROs to improve their efficiencies. Only subsequently did traditional site-based trials become the accepted standard due to regulatory impediments and infrastructural deficits.

Acceleration During the COVID-19 Pandemic

The year 2020 witnessed an turning event for DCTs by virtue of the COVID-19 pandemic. With lockdowns and restrictions against any physical visits to trial sites, regulatory agencies issued emergency guidance along with relaxing regulations to facilitate decentralized ways of working. Sponsors and contract research organizations (CROs) were quick to embrace remote technologies to maintain the continuity of their trials. This shift showcased that DCTs could maintain their data integrity while being less burdensome for the patient.

Regulatory and Industry Support

In the post-pandemic period, regulatory bodies like the FDA, EMA, and MHRA have put DCT methods on record through the publication of guidelines to support them. On the other hand, industry stakeholders (pharma companies and software vendors) have been investing in decentralized trial platforms increasing their market acceptance.[6,7,8]

Recent Growth Trends

- The adoption of DCT by Pharma and CROs - Leading Pharma companies have started to include DCT elements in their clinical trial designs.
- Technological Advancements-AI-based analytic, the blockchain for secure-database management, and remote monitoring tools continue improving DCT models.
- More Patients-Centric- The major concern of regulatory bodies and sponsors is to try and minimize the burden to patients and increase the diversity of participants in clinical trials.
- Expansion from Traditional Therapies- DCT started off with chronic conditions, but has recently found its niche also in more complex disease areas such as oncology and rare diseases.

ADVANTAGES OF DCTS

Expanded patient access

DCTs break geographical barriers, allowing participation from a much larger patient pool, including those in rural and low-resourced areas. DCTs facilitate the ability of patients to participate from home; they play a role in improving inclusivity and increasing diversity in clinical research, achieving more representative study populations and better generalizability of trial outcomes.

Enhanced patient retention and compliance

DCTs enhance retention of patients and compliance to trial protocols by minimizing the frequency of what could be burdensome site visits. Digital reminders alongside remote consultations with a treating physician and wearables help ensure participation throughout the study, thus leading to high-quality data and more reliable results from the study.

Cost and Time Efficiency

DCTs work to bring down the logistical costs of traditional trial sites, including travel reimbursements, site infrastructure, and human costs. While on-site drug delivery and remote monitoring expedite recruitment and data collection, this expedites all study timelines and does impact the cost of drug development lowering.

Real-World Data Collection

DCTs continuously collect real-world patient data with sensors and wearables, telehealth consultations, and mobile health applications. The main benefit of this practice is to obtain insights on treatment effects in real-life settings which enhances the external validity of the trial and allows better post-marketing surveillance of new investigational therapies.[9,10]

CHALLENGES OF DCTS

Compliance and Regulatory Hurdles

Global variations in the regulatory requirement have prohibited the implementation of DCT across regions. Maintaining compliance with informed consent, data privacy laws (GDPR, HIPAA), and Good Clinical Practice (GCP) guidelines is an ongoing collaboration effort among regulatory agencies, sponsors, and technology providers.

Digital Literacy and Technology Access

Not every patient has the smartphone, stable internet connection, or digital literacy required to maneuver through the sites where remote trial activity is occurring. Tackling the widening gap in digital ability is important to ensure

equitable trial participation with a need for easier user interfaces, technical assistance, and alternative methods of engagement for those who cannot navigate technology accessed trials.

Confidentiality and Data Security Issues

When Digital Health Technologies (DHTs) are used, one of the major concerns is data security about the digital medium by which communications take place. The patient faces threats concerning security, integrity, and confidentiality of data communicated through these technologies. This necessitates providing encrypted communication, applying secure cloud storage, and ensuring compliance with data protection and privacy laws to build trust in patients and protect sensitive health information from compromise due to a breach.

Remote Monitoring Limitations

It must be emphasized that although wearable devices and telemedicine provide real-time health data, in-person clinical assessments are unfortunately necessary in some situations. Certain conditions require laboratory tests, imaging, or physical examinations that with even the most advanced technology could not be delivered remotely. These trials may require some sort of hybrid model wherein remote evaluations may be put in the balance with on-site evaluations.[11,12]

IMPACT OF DIGITAL HEALTH TECHNOLOGIES ON DCTS

Remote and wearable monitoring

Continuous capture of vital signs, activity, and treatment responses is being realized using wearable or mobile sensors and health devices. These thus improve the accuracy and reliability of data while ensuring real-time and timely intervention for any change in the patient's condition since they reduce recall bias. This increases the efficiency of studies as well as monitoring of safety.

Telemedicine and Virtual Consultations

Telemedicine enables the researcher to conduct virtual consultations with the patient relative to treatment response and other concerns of the participant. It saves time and reduces travel through technology to improve the convenience of patients and foster access to clinical research even for the geographically distant populations.

Electronic Informed Consent (eConsent)

Electronic eConsent solutions allow potential participants to have real-time digital access and view trial procedures through which they will fully understand the study protocol before enrolling. Use of such multimedia tools as video and interactive feature significantly increases understanding, therefore improving engagement during participants' settled regulatory compliance and documentation efforts by having those entities enroll.

Artificial Intelligence and Data Analytics

AI techniques have been used to mine huge amounts of patient data from wearables and digital sources. It enhances the risk prediction, detects anomalies in real time, and will help in the efficient identification of eligible participants for trial optimization with respect to trial design, leading to better precision in clinical research and adaptability to methodologies.

Blockchain for Data Security

Through a secure, tamper-proof environment, a blockchain is able to store patient data, thereby increasing the trust and transparency of direct-to-consumer trials. Since blockchain provides immutable records for trial-related transactions to

prove data integrity while decreasing chances of fraud, this technology enables safer sharing of data and regulatory compliance in decentralized research settings.[13,14]

IMPORTANCE OF REGULATORY FRAMEWORKS IN DCTS

Indeed, regulatory frameworks are essential to the all-important realization and running of DCTs. Such frameworks keep DCTs on a par with traditional clinical trials in terms of rigour, integrity and safety but also span the special challenges of conducting a trial outside the facility using remote technologies.

1. **Patient Safety and Data Integrity**: The use of regulations protects trial participants carried out in a decentralized manner. By ensuring the credibility, verification, and trustworthiness of the data collected, these frameworks provide guidelines for data handling and technology use, and monitoring of patients, minimizing the risks implicated with the remote health assessments.
2. **Compliance with Ethical Standards**: Regulatory agencies have been tasked with laying down ethical standards for the protection of participants' rights, including informed consent procedures. Given that DCTs are essentially remote, they must be internally qualified through ethical standards that ensure that consent processes particularly related to DCTs are well spelled out, with clear and simple language to furnish full understanding of participation and risks to participants.
3. **Standardization Across Jurisdictions**: Since DCTs normally involve more than one region or country, regulatory frameworks ensure that trials meet local regulations and harmonize procedures between different jurisdictions, which will be a ratification for global DCT trials, leading to easier participant recruitment.
4. **Technology and Innovation Adoption**: Regulatory frameworks are critical in promoting innovation as they outline regulations for safe usage of technologies in clinical trials. DCTs, which are reliant on digital health tools, remote monitoring devices, and telemedicine, must have their appropriate validation and security before the regulators approve them for clinical trial undertaking.
5. **Flexibility in Trial Design**: The regulatory frameworks can be flexible in trial designs keeping the specific nature of DCTs in mind as they happen to ensure safety of the patients. Such changes in trial designs would include the unique approach to informed consent, remote collection of data, and home delivery of investigational products, thus evolving to the various paradigm shifts in trial designs by keeping regulatory compliance intact.
6. **Risk Management**: Regulatory authorities in the main issue some guidelines then for risk-based monitoring, especially for DCTs. Since the very nature of DCTs includes remote data collection, risking the process in real time must be carried out continuously to ensure participant safety and data validity under regulatory supervision to control emerging risks.
7. **Facilitating Faster Approvals**: Regulatory frameworks can streamline the approval process for DCTs by providing clear guidelines, helping sponsors and trial organizers navigate regulatory requirements efficiently. This can lead to faster trial initiation and potentially faster access to innovative treatments for patients.[15,16]

FDA GUIDELINES ON DECENTRALIZED CLINICAL TRIALS (DCTS)

Decentralised Clinical Trials have risen in prominence in clinical research giving enhanced access, efficiency, and patient engagement. But with all these advantages, the implementation of DCTs must be in accordance with the regulatory requirements for the safety of patients, integrity of data, and compliance with ethical conduct. The FDA developed a regulatory framework for the DCTs and its guidance covers numerous elements, including remote

monitoring of patients, telemedicine, electronic informed consent (eConsent), security of data, and the responsibilities of the IRBs.

Regulatory Landscape for DCTs in the U.S.

DCTs have the assumed capability in FDA's mind of improving efficiency in clinical trials with the respect and safety of the trial subjects. In terms of regulation within the U.S., DCTs follow the same rigorous regulatory standards as traditional clinical trials conducted at physical sites. And the sponsors and investigators must also comply with FDCA, GCP guidelines, and the ethical principles presented in the Common Rule.

Digital health technologies, telemedicine, and remote monitoring are all components of decentralized clinical trials (DCTs), all of which need clear regulatory oversight. In this regard, the FDA is also working with the Office for Human Research Protections (OHRP) and the Department of Health and Human Services (HHS) in ensuring ethics and science compliance in trials that are conducted in a decentralized manner. All compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations is also essential to safeguard participant privacy in trials conducted remotely.[17,18]

Key Guidance Documents from the FDA

The FDA had a bunch of guidance documents on regulatory expectations regarding DCTs, which clarify things: a roadmap for any sponsor, investigator, or CRO, as they work through the integrity of decentralized trial methodology.

Digital Health Technologies for Remote Data Acquisition in Clinical Investigations" (2023): This guideline describes recommendations for selecting, validating, and applying digital health technologies (DHTs) in clinical investigation. It recommends assuring accurate, reliable, and secure data gathered from remote devices.

Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency" (2020): Issued at the time of pandemic, this guidance contained recommendations for conducting remote clinical trials along with issues related to safety of patients, flexibility in regulatory processes, and changes in protocols.

Use of Electronic Informed Consent" (2016): This document offers guidance on the application of electronic consent in clinical trials-from the assurance of informing a participant of the study before enrollment. It also highlights the need for electronic platforms to be in compliance with GCP and IRB requirements.

Patient-Focused Drug Development (PFDD) Guidance": It encourages the inclusion of the patient's perspective into the design of the trials as in-thinking decentralized priorities of making trials easy and inviting for patients.[19,20]

Requirements for Remote Patient Monitoring, Telemedicine, and eConsent

Remote Patient Monitoring

Remote patient monitoring is one of the aspects of DCTs in the sense that it allows data collection to take place continuously but without in-person visits. The technology, from wearable sensors to mobile health apps and connected medical devices, must be proven accurate and clinically relevant through processes mandated by the FDA along the lines of any digital health technology. Such devices should be able to offer trustworthy, real-time health data, which can be utilized for decision-making in clinical trials.

However, the FDA ensures that remote monitoring does not compromise the safety of the patient. The sponsors should prepare favorable protocols to detect any adverse events or changes, address all crucial health concerns without delay, and comply with the legal requirements of sponsor registration. However, the regulatory framework also requires that sponsors create mechanisms through which data can be transmitted and stored and they need to comply with cybersecurity standards for maintaining patient privacy.

Telemedicine in DCTs

Telemedicine is a very important aspect of DCTs since it permits the remote consultation, evaluation, and follow-up of patients. The FDA appreciates the role telemedicine can play in promoting a degree of access and convenience to patients, but it states that virtual visits must be like in-person visits in terms of the level of clinical oversight.

Ironically, telemedicine platforms should also subject investigators to the HIPAA rules as far as patient confidentiality is concerned. The other thing that the clinical trial protocol will define is the procedure required for carrying out virtual assessments, with possible technical failure and limitations of physical examination in mind. Hybrid trials with telemedicine will also be promoted by the FDA, which will comprise, from time to time, in-person visits that will be necessary for physical assessment or laboratory tests.

Electronic Informed Consent (eConsent)

By giving the right to participants to review and sign informed consent documents online, eConsent improves trial efficacy and enhances patient engagement. The FDA supports the use of eConsent, provided it fulfills ethical and legal obligations. The eConsent platform should be developed to ensure that participants adequately understand the objectives, risks, and benefits of a study making use of multimedia tools such as video, animation, and interactive content.

Furthermore, the FDA prescribes that eConsent platforms generate verifiable documentation of consent for purposes that IRBs and regulatory bodies could review in case of participant approvals needed. Encryption and audit trail security would be introduced to prevent tampering with data and unauthorized access.[21,22]

Data Collection, Security, and Integrity Concerns

Requirements for Data Collection

It is a requirement that the FDA specifies that data obtained on DCTs are adhering to the scientific standards of validity and reliability. All digital health technology to be used in the trial should be validated for its accuracy and consistency. The sponsor should use standard data formats for efficacious regulatory inspection, apart from ensuring interoperability with active clinical trial management systems.

Security Measures

Patient data security is a very big area of concern in DCT. The significant reliance on cloud-based platforms and remote monitoring tools compounds the concern. The FDA also reiterates the fact that patient information confidentiality and security must be ensured besides compliance with data protection laws such as HIPAA and GDPR. This could be ensured by measures like encryption, two-factor authentication, and secure cloud storage, against the risk of possible data breaches. while also guaranteeing interoperability with already existing clinical trial management systems.

Data Integrity and Traceability

In essence, integrity is therefore one of the critical aspects for approval of a regulatory body. The FDA states that all these digital trial data must be traceable, with assurance of the existence of audit trails for them. The investigators should be motivated in developing clear procedures preventing manipulation, timely reporting, and resolution of any disparity for remote data collection. The agency also advices use of blockchain to improve transparency and reliability associated with data.[23,24]

Role of Institutional Review Boards (IRBs) in FDA-Regulated DCTs

Institutional Review Boards (IRBs) are implicated in upholding ethical standards and regulatory mandates as it pertains to DCTs. Essentially, they are charged with maintaining the rights, safety, and confidentiality of subjects enrolled in decentralized trials. Respectively, protocols concerning remote monitoring, telemedicine, and eConsent go through the IRB review process in which the IRB safeguards the welfare of the patient. They judge whether a digital platform offering information during patient interaction presents easily comprehensible information complying with ethical standards. Alongside these duties, the IRBs maintain ongoing compliance with the various FDA regulations by requiring the sponsors and investigators to submit regular reports to ensure the protection of their human subjects throughout the trial.

FDA's Stance on the Use of Artificial Intelligence (AI) and Wearable Devices

AI in Clinical Trials

FDA acknowledges that AI is playing an important role in clinical trials, especially in patient recruitment, risk prediction and data analysis. However, the agency insists that AI-based models will have to be clear and interpretable when used within DCT. Before using any AI-based algorithm for a regulatory submission, he must conduct validation studies to show accuracy of use, including reliability and fairness in all cases. AI does help in identifying eligible participants, real-time health data analysis and prediction of adverse events; however, FDA insists on transparent documentation of processes of AI decision making to identify and alleviate biases and ensure replicability in clinical research findings.

Wearable Devices in DCTs

Wearable devices such as smart watches, continuous glucose monitors, and ECG patches enable data collection on a significant level for decentralized clinical trials (DCTs). Certain wearables are classified by the FDA as medical devices and so must meet regulatory approval standards prior to use in clinical trials. The FDA Digital Health Pre-Cert Program offers a way for wearable devices to be assessed for safety and efficacy. It is important that sponsors ensure that the wearables used in DCTs yield clinically meaningful and reproducible data. Similarly, the agency requires embedding wearables-derived data to trial protocols considering patient safety and regulatory requirements.[25,26]

EMA GUIDELINES ON DECENTRALIZED CLINICAL TRIALS (DCTS)

This is a brand new regulatory framework from the European Medicines Agency (EMA) to authorize Decentralized Clinical Trials (DCTs) while ensuring that ethical, scientific, and legal criteria for the conduct are satisfied. The recognition by EMA is that DCTs have large advantages related to the accessibility of patients and efficiency of trials, although complying with very strict standards of data integrity, patient safety, and regulatory oversight, as have been put forth by it. The agency's specific guidance foci include telemedicine, remote monitoring, e-consent, personal data

affected by the General Data Protection Regulation (GDPR), and the Ethics Committees. AI, wearable devices, and digital health technologies are also addressed by EMA in the decentralized trial context.

Regulatory Landscape for DCTs in the European Union

In the European Union (EU) within DCTs, the most significant and applicable regulations are the Clinical Trials Regulation (CTR), Regulation (EU No 536/2014), and Good Clinical Practice (GCP) guidelines (ICH E6(R2)). The CTR, which became fully applicable in 2022, provides for a harmonized process for clinical trial applications and assessments, as well as for overseeing all trial conduct in EU Member States. It allows for decentralized elements into trials while ensuring the safety, efficacy, and ethical principles remain intact.

Apart from the CTR, decentralized trials must comply with the GDPR (General Data Protection Regulation) (EU 2016/679), which sets the rules for the collection, processing, and storage of patients' data. These trials need to be especially compliant with GDPR because of increased digital health technologies and remote data collection. Another regulation that applies to wearables and digital health tools in clinical research is the Medical Devices Regulation (MDR) (EU 2017/745).

The regulatory framework in the EU allows sponsors of these trials to use decentralized approaches while still prioritizing patient rights and safety. The difference is that the interpretation of such DCT regulations could vary from one member state to another, thus sponsors ought to interface with regulators in different member states.[27,28,29]

Key Guidance Documents from the EMA

These documents have proven vital for sponsors, investigators, and research organizations that need appropriate guidance on the implementation of DCTs:

- **"Guidance on the Management of Clinical Trials During the COVID-19 Pandemic" (2020):** This document first incorporated regulatory flexibility for the application of DCTs, including remote monitoring, telemedicine, and drug shipment directly to patients.
- **"Recommendations on Decentralized Elements in Clinical Trials" (2022):** D Developed jointly with the Heads of Medicines Agencies (HMA), Clinical Trials Coordination Group (CTCG), and EMA in support of good practices for DCTs while in line with GCP and regulatory requirements.
- **"Guideline on Computerized Systems and Electronic Data in Clinical Trials" (2023):** The document describes requirements for various digital tools applied in clinical trials regarding data integrity, audit trails, and compliance with GDPR
- **"Guideline on Electronic Informed Consent (eConsent)" (2021):** It offers recommendations for the conduct of eConsent, ensuring the process is transparent, comprehensible, and overseen ethically.

Requirements for Telemedicine, Remote Monitoring, and eConsent

Telemedicine in DCTs

It promotes approach to distance clinical trials between DCTs enabled by telemedicine. Further-away real-life, remote follows and digital patient-reported outcomes are possible with telemedicine. The EMA supports telemedicine though it requires that sponsors take appropriate measures to comply with national regulations in each individual member state. Telemedicine platforms must:

- Comply with GDPR and national laws on data protection.

- Provide equivalent quality of care as in-person visits.
- Allow for secure, confidential communication between patients and investigators.
- Recognize all teleconsultations for their regulatory review.

The investigators will have to consider as whether telemedicine might be appropriate in the context of the specific trial population to ensure virtual assessments remain with the quality to the detriment of data or the patient's safety.[30,31]

Remote Patient Monitoring

Remote patient monitoring is possible in DCTs as per EMA requirements as long as the devices and technologies employed are validated for accuracy and reliability. Hence, it is the sponsor's responsibility to ensure that:

- Digital health devices (e.g., wearables, biosensors) meet MDR requirements.
- Data collected remotely is secure, encrypted, and traceable.
- Protocols define how adverse events identified through remote monitoring will be managed.

It may sometimes be necessary to mix both remote and in-person assessments to achieve complete patient coverage.

Electronic Informed Consent (eConsent)

In the Europe-based DCT world, eConsent is, although most possibly viewed as unethical, somewhat justified if it meets certain ethical and legal standards. The EMA guidelines state that eConsent systems should:

- Inform the subjects adequately about trial objectives and ancillary considerations such as risks and benefits.
- Provide notable interactive supplements such as videos, quizzes, and live Q&A sessions.
- Include clear records and audit trails of eConsent documentation for regulatory review purposes.
- Enable patients to withdraw consent easily and at any time.

The eConsent platforms must stay true to the letter of GDPR when it comes to safeguarding the privacy and data security of its participants.[32,33]

Data Protection Considerations Under GDPR

DCTs consist of remote data collection and digital health technologies. Thus, ensuring compliance with GDPR is pivotal for the safety and integrity of patient and data confidentiality.

Some major aspects of GDPR with respect to DCTs:

- **Lawful Basis for Data Processing:** The sponsor is to specify the reasonable legal basis on which the patient data be collected, usually referring to Article 6 and Article 9 of GDPR
- **Data Minimization:** Only the necessary data should be associated with a patient, which includes collecting and keeping patient data.
- **Security Measures:** The data must be encrypted, anonymized, or pseudonymized so that no one accesses them
- **Informed Consent:** Patients must be informed how data will use, share, and store.
- **Data Subject Rights:** A patient can gain, amend or erase their data.

A breach of the rules of the GDPR is bound to attract hefty penalties, thus making data protection a critical factor in the implementation of DCTs in the EU.

Role of Ethics Committees in EMA-Regulated DCTs

Ethics Committees (ECs) are responsible for watching over DCTs in the EU from a dual perspective of ethical and patient safety. Majorly, they will:

- **Reviewing Protocols:** This is where ECs examine whether decentralized adjuncts (e.g., telemedicine, remote monitoring) are aligned with ethical standards.
- **Evaluating Informed Consent Procedures:** eConsent must be clear, transparent, and ethically sound.
- **Ensuring Patient Safety Measures:** ECs examine to what extent investigators report adverse events in remote settings.[34,35,36]
- **Assessing Data Privacy Protections:** GDPR compliance and other general ethical principles will be at the forefront of approval by the EC.

Since DCTs may involve multi-country participation, Ethics Committees from different member states must work together to achieve a harmonized ethical framework for the oversight of DCTs.

EMA's Approach to AI, Wearables, and Digital Tools

Artificial Intelligence in DCTs

The EMA reports that AI can improve clinical trials through data analysis, patient monitoring, and predictive modeling; however, any such applications must comply with the provisions of the EU Artificial Intelligence Act and the Medical Devices Regulation (MDR). Additionally, EMA advocated transparency, bias mitigation, and algorithm validation so that AI-based decisions would be made under ethical and scientific integrity standards. Documentation must meet regulatory requirements by showing robustness about the model, data used to train it, and performance metrics regarding the outcome from it.

Wearables Devices

Wearable medical devices have been an essential component of Decentralized Clinical Trials (DCTs), allowing for continuous remote monitoring of vital signs, physical activity, and treatment adherence. These devices must be CE-marked under MDR, so that the accuracy, reliability, and safety can be assured. The agency further demands that validation studies be conducted to compare data obtained from wearables to data obtained from traditional clinical assessments. It is the sponsors' responsibility for ensuring secure data transmission as well as the provision of an exhaustive protocol on how the wearable devices are integrated into trial designs.

Digital Tools

Integrating digital platforms, mobile applications, and electronic health records (EHRs) for better patient engagement and real-world evidence is emphasized by EMA. But these tools should go further to guarantee data privacy and security in complying with the GDPR in order not to violate any patient privacy issues. EMA is in favor of the use of blockchain and encrypted cloud storage for the safeguarding of trial data integrity. Besides, any digital tools utilized for telehealth, ePRO (electronic patient-reported outcomes), and eConsent need to be evaluated by the regulatory authority with respect to compliance with ethics and legality in the EU.[37,38]

COMPARATIVE ANALYSIS: FDA VS. EMA GUIDELINES

Aspect	FDA Guidelines (U.S.)	EMA Guidelines (EU)
Regulatory Framework	They will be governed by U.S. Department of Health and Human Services approval rules in accordance with 21 CFR Part 312, 21 CFR Part 50, ICH GCP (E6 R2), and HIPAA for data privacy.	On the other hand, the Clinical Trials Regulation (EU 536/2014), ICH GCP (E6 R2), GDPR (EU 2016/679), and MDR (EU 2017/745) applicable to the medical devices will prevail.
Key Guidance Documents	- FDA Guidance on Decentralized Clinical Trials (2023)	- EMA Guidance on Decentralized Elements in Clinical Trials (2022)
	- FDA COVID-19 Clinical Trials Guidance (2020)	- EMA Guidance on eConsent (2021)
	- FDA Use of Electronic Informed Consent (2016)	- EMA Guidelines on Computerized Systems & Electronic Data (2023)
	- FDA Guidance on AI in Drug Development (2023)	- GDPR Compliance Guidelines for Clinical Trials
Ethical Oversight	All studies are approved by Institutional Review Boards (IRBs) for patient safety, informed consent and risk analysis.	These are undertaken by Ethics Committees (ECs) with compliance checks for GDPR and country-specific regulations.
Patient Safety & Risk Management	Sponsors should apply RBM and ensure compliance with FDA safety reporting.	It requires RBQM and Safety Risk Assessment Plans (SRAP) as per the EMA guidelines.[39,40]
Telemedicine Use	Allowed with the exclusivity of state laws and HIPAA patient data security.	It is allowed but governed differently by each member state in the EU; thus, requiring additional approvals for some countries.
Remote Patient Monitoring (RPM)	Permitted if the devices are FDA-cleared medical devices with proper standards in validation.	Permitted according to MDR EU (2017/745), but requires CE marking compliance and data protection according to GDPR.
Wearable Devices & Digital Health Tools	Allowed if cleared by the FDA under 510(k) or De Novo pathways.	Permitted under MDR (EU 2017/745) and IVDR (EU 2017/746), requiring stricter validation.
Artificial Intelligence (AI) in DCTs	Acceptable, assuming that audit trails, verification of identity, and compliance with 21 CFR Part 11 are assured.	Allowable, but it must comply with GDPR, which necessitates extra data protection and specific national approvals.
Electronic Informed Consent (eConsent)	Allowed, with audit trails, identification, and 21 CFR Part 11 compliance required.	Allowed subject to further compliance with GDPR, including security of the data concerned and possible approvals in the country concerned.
Data Privacy & Security	HIPAA governing patient de-identification and encryption of data.	GDPR governing with stringent checks for patient rights, allergenization of data processing, and explicit consent for processing.
Decentralized Drug Dispensing	Prescription medicines can be shipped to patients, although with strict tracking and documentation.	Allowed, but governed by national regulations, while some restrict direct shipments.
Remote Site Audits & Monitoring	Allowed using a Risk-Based Monitoring (RBM) framework and under FDA oversights.	It requires site and centralized monitoring with a stringent quality control approach.
Use of Mobile Applications	Mobile health apps are permitted if approved by the FDA as medical devices.	Permitted under MDR, GDPR, and national legislation.
Use of Blockchain & Decentralized Ledgers	FDA is conducting research on blockchain's potentials related to clinical trials transparency; however, they do not have guidance to date.	EMA is a lot more hyper-cautious, requiring adherence to GDPR and placing data sovereignty conditions.
Real-World Evidence (RWE) & Data Use	Encourages RWD and RWE for regulatory decisions.	Integrates RWE but under stricter validation and patient data protection.
National vs. Multi-Country Coordination	It is regulated and administered at the federal level, creating a uniform framework for DCT implementation.	Multinational coordination is required, which gives rise to variability in approvals among EU member states.
Patient Recruitment & Retention Strategies	Digital recruitment tools and telehealth strategies are encouraged to promote patient diversity.	Requires sponsors to ensure an equal access of regions across the EU, complicating recruitment.
Regulatory Flexibility	Much more adaptive and conducive to innovation, allowing sponsors to speed up the	It is more structured and stringent, requiring extensive pre-approvals before the deployment of

	deployment of new technologies.	new DCT components.
Challenges in Implementation	Different states have their own telemedicine laws regarding variability in patient engagement.	In-country regulations create differences in trial execution.
	Data privacy laws (HIPAA) are not as comprehensive as GDPR.	Stricter data protection rules added complexity to design of DCT.
Strengths	Flexibility and adaptability to innovation encourage telemedicine, AI, and wearables for DCTs because of a quicker approval process for DCTs new technologies.	Stronger data privacy protections present in GDPR: more rigorous oversight by Ethics Committees multimodular harmonization under Clinical Trials Regulation (EU 536/2014).
Weaknesses	Less stringent data privacy regulations (HIPAA does not cover the breadth and depth of GDPR).	Approval process with many levels of review. Compliance burden for DCT is stricter. Differences in national laws governing telemedicine and eConsent relative to EU states.[41,42]

CHALLENGES AND GAPS IN CURRENT REGULATORY FRAMEWORKS

1. Gaps in Global Regulation

Decentralized clinical trials (DCTs) face many challenges due to differences in applicable regulations in the regions where DCTs are deployed. The FDA and EMA issued distinctly different guidelines concerning remote monitoring, eConsent, and secondary use of digital health technologies, making the endeavor of global harmonization almost impossible. This creates additional work for sponsors to gain approval in individual countries regarding local, regional, and international approval processes, local and institutional ethics committee reviews, and data protection laws, all of which adds to trial delays.

2. Issues in Compliance with Data Protection and Security

Complicated systems of regulation limit the scope of data collection, sharing, and transfer across countries under laws like GDPR in the EU and HIPAA in the U.S. Oftentimes, these laws obstruct one another, becoming very stringent on their conflicting requirements for the tests conducted. It remains a challenge to maintain patient privacy while achieving a secure electronic data capture (EDC) and streaming live follow-ups with patients with varying legal requirements for safeguarding measures.

3. Ethical Concerns with eConsent and Patient Autonomy

Although eConsent improves in terms of availability, it increases ethical concerns regarding a patient's ability to comprehend, digital literacy, and coercive concern. The frameworks of regulation do not include any standards on methods of verifying patients' identities or the specifics of how to monitor whether or not their decisions are informed, nor do they outline how to divide disparities in access to digital technology, particularly for underserved populations.[43,44]

4. Validation and Approval of Digital Health Technologies

Although both the FDA and EMA are pro-digital health, the pathway through which remote-controlled devices and wearables can be defined under "AI tools" is complicated and non-uniform. Generally, one would get speedier approvals via the FDA, while the EMA will require a full clinical validation under MDR before entry into the market. The lack of harmonized criteria leads to restrained uptake in the use of such emerging technologies in DCTs.

5. Limited Oversight of AI and Machine Learning in Clinical Trials

The use of AI for patient monitoring, data analysis, and automated decision-making has risen and brought concerns regarding bias, algorithmic transparency and regulatory oversight. The existing frameworks cannot adequately address the validation of trial data generated by AI, resulting in regulatory vagueness. Accordingly, more formidable audit measures and guidelines should be put in place to ensure that decisions made by AI shall equally identify with ethics and the canons of scientific integrity.

6. Challenges in Remote Monitoring and Decentralization

Despite some regulatory backing of remote patient monitoring (RPM), telehealth, and home-based trial visits, there are still notable challenges to device standardization, data reliability, and oversight by physicians. Some of the regulations demand frequent site visits or higher monitoring requirements, which go against the set aim to make these protocols more decentralized and, consequently, more efficient in conducting trials and lowering their costs.

7. Inconsistencies in Ethics Review Processes

In the U.S., Institutional Review Boards (IRBs) supervise clinical trials in the country, while in the EU, there are multiple Ethics Committees (ECs) in member states that have to give their approval before a trial can take place, leading to increased complexity for multi-country studies. There is no centralized ethics review system in the EU to further delay, make the process inconsistent, and add extra administrative burdens.[45,46]

8. Lack of Standardized DCT-Specific Guidelines

The agencies talk of generic digital health, while currently, no particular extensive, accurate guidance exists for a fully decentralized trial. Policy sponsors have compliance doubts as there are unclear integral definitions of the responsibilities of remote sites, investigator oversight with respect to activities, and data handling protocols. For specific operations related to DCTs, there is a need for more standardized global frameworks in place.

FUTURE DIRECTIONS AND RECOMMENDATIONS

1. Convergence of Global Regulatory Frameworks

A common regulatory pathway would benefit Decentralized Clinical Trials (DCTs) globally. The FDA, the EMA, and all others should join forces in developing common guidelines concerning remote monitoring, eConsent, and AI-based digital health technologies. Such ICH guidelines for DCTs would, of course, fill different gaps and further the purposes of efficiency in international clinical trials.

2. Strengthening Data Privacy and Security Measures

Future regulations must provide for cross-border data sharing challenges, such as alignment between the GDPR, HIPAA, and other privacy frameworks. Secure cloud platforms, blockchains, and encryption will provide an extra layer of data security while keeping pace with existing and foreseeable privacy laws.[47,48]

3. Standardized Validation of Digital Health Technologies

Regulatory agencies are expected to create well-defined pathways for the consideration of AI tools, wearables, and remote monitoring devices in clinical trials. Universal validation standards under the auspices of the FDA's Digital Health Pre-Cert Program and EMA's MDR would serve to expedite the device approvals and market entries.

4. Expanding Ethical and Regulatory Oversight for AI in DCTs

Wherever AI has entered clinical trials, the way is the need for regulators to set clear lines for AI transparency, bias mitigation, and accountability in decision-making. Such a framework for ethics and science will ensure the clear acceptance and compliance of AI-enabled patient monitoring, automated trial management, and predictive analytics.

5. Enhancing Remote Monitoring and Virtual Trial Infrastructure

The future regulatory environment would favor widespread adoption of telehealth, remote assessments, and hybrid trials models. Standardized operating procedures for remote investigator oversight, digital endpoints, and real-world evidence collection would enhance access and efficiency.

6. Adoption of Decentralized Ethics Review Models

The EU Should Set A Central Ethical Committee For Review So That The Approval Process For DCTs Across Many Countries Is Accelerated. This Would Be The Equivalent Of The U.S. IRB Model And Would Eliminate The Time Loss Caused By Multiple National Ethical Reviews And Will Make Global Trials Viable All Over Again.

7. More Inclusive and Patient-Centric DCT Models

Regulatory frameworks must pave the way for diversity within clinical trials by removing the digital barriers, ensuring rural accessibility, and providing eConsent platforms in multilingual. Policies should mandate including underrepresented populations in DCT, which will enhance the generalizability of these clinical findings.

8. Real-Time Regulatory Adaptation for Emerging Technologies

Where rapid change is the order of the day for digital health, so adaptive guidelines need to be pursued by regulators in step with the change brought by AI, wearables, and telemedicine. The establishment of real-time regulatory pathways, pilot programs, and sandbox testing environments will encourage much faster innovation in DCTs.[49,50]

CONCLUSION

Digital health technologies have changed the paradigm of clinical trial research for decentralized clinical trials, improving the accessibility and engagement of patients and the collection of data. The regulatory frameworks governing decentralized clinical trials differ across the Food and Drug Administration and the European Medicines Agency, thus creating a challenge for the harmonization of trials globally. However, while both emphasize issues regarding patient safety, data integrity, and ethics, they differ on remote monitoring requirements, use of eConsent, and data privacy regulations (HIPAA vs. GDPR).

However, with the advent and rapid rise of remote clinical trials, calls are being made for more harmonized regulatory approaches to ease international trials. It is critical to address concerns like data security and privacy, interoperability, and regulatory divergence, as these issues will be vital for compliance and protection for innovation. Compliance of future regulations should also consider technological advancement with high potential such as AI and blockchain, for the well-functioning establishment of trial oversight. Globally coordinated strategies can seriously address issues of efficiency, reliability, and access to DCT drug development.

REFERENCES

1. Chen J, Di J, Daizadeh N, Lu Y, Wang H, Shen YL, Kirk J, Rockhold FW, Pang H, hao J, He W, Potter A, Lee H. Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective. Clin Transl Sci., 2025 Feb; 18(2): e70117.
2. Ghadessi M, Di J, Wang C, Toyoizumi K, Shao N, Mei C, Demanuele C, Tang RS, McMillan G, Beckman RA. Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective. Orphanet J Rare Dis., 2023 Apr 11; 18(1): 79.
3. Dockendorf MF, Hansen BJ, Bateman KP, Moyer M, Shah JK, Shipley LA. Digitally enabled, patient-centric clinical trials: shifting the Drug Development Paradigm. Clin Transl Sci., 2021; 14: 445–59.
4. Van Norman GA. Decentralized clinical trials. JACC Basic to Transl Sci., 2021; 6: 384–7.
5. US FDA. (2021) Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.
6. Copland RR, Hanke S, Rogers A, Mpaltadoros L, Lazarou I, Zeltsi A, Nikolopoulos S, MacDonald TM, MackenzieThe Digital Platform and Its Emerging Role in Decentralized Clinical Trials. J Med Internet Res., 2024; 26: e47882.
7. Silva DJ, Nelson BE, Rodon J. Decentralized Clinical Trials in Early Drug Development-A Framework Proposal. J Immunother Precis Oncol, 2024 Aug 19; 7(3): 190-200.
8. Harshada Sandeep Jadhav, Pratiksha Anil Salunkhe, Sunil Maniraj Yadav, Dr. Shoheb Shaikh, REGULATORY AFFAIRS IN THE PHARMACY MODULES. World Journal of Pharmaceutical Science and Research, 2024; 3(6): 207-223.
9. Betcheva L, Kim JY, Erhun F, Oraiopoulos N, Getz K. Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment. Ther Innov Regul Sci., 2023 Sep; 57(5): 1081-1098.
10. Khozin S, Coravos A. Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations. Clin Pharmacol Ther., 2019; 106: 25–27.
11. Sine S, de Bruin A, Getz K. Patient engagement initiatives in clinical trials: recent trends and implications. Ther Innov Regul Sci., 2021; 55(5): 1059–1065.
12. Mensah NK, Adzakpah G, Kissi J, Taylor-Abdulai H, Johnson SB, Agbeshie PA, Opoku C, Abakah J, Osei E, Agyekum AY, Boadu RO. Health Professionals' Ethical, Security, and Patient Safety Concerns Using Digital Health Technologies: A Mixed Method Research Study. Health Serv Insights, 2024 Nov 26; 17: 11786329241303379.
13. Huhn S, Axt M, Gunga HC, Maggioni MA, Munga S, Obor D, Sié A, Boudo V, Bunker A, Sauerborn R, Bärnighausen T, Barteit S. The Impact of Wearable Technologies in Health Research: Scoping Review. JMIR Mhealth Uhealth, 2022 Jan 25; 10(1): e34384.
14. Shin G, Jarrahi MH, Fei Y, Karami A, Gafinowitz N, Byun A, Lu X. Wearable activity trackers, accuracy, adoption, acceptance and health impact: a systematic literature review. J Biomed Inform, 2019; 93: 103153.
15. de Jong AJ, van Rijssel TI, Zuidgeest MGP, van Thiel GJMW, Askin S, Fons-Martínez J, De Smedt T, de Boer A, Santa-Ana-Tellez Y, Gardarsdottir H; Trials@Home Consortium. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective. Clin Pharmacol Ther, 2022 Aug; 112(2): 344-352.
16. Coyle, J. *et al*. Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. Br. J. Pharmacol, 2022; 88: 1031–1042.

17. Park J, Huh KY, Chung WK, Yu KS. The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance. Transl Clin Pharmacol, 2024 Mar; 32(1): 41-51.
18. Makvana, S. H., Deshpande, S., & Zaveri, M., Comparative Analysis of Drug Labeling Requirements in The USA And India: Regulatory Frameworks And Compliance Standards. International Journal of Pharmaceutical Sciences, 2024; 2(6): 701-707.
19. Amaresh K, Salimath G, Ganachari MS, Devarinti RS, Kumar U. A comparison of regulatory approval of clinical trial protocol with different countries. International Journal of Clinical Trials, 2021 Jul; 8(3): 260-6.
20. De Sutter E, Barbier L, Borry P, Geerts D, Ioannidis JPA, Huys I. Personalized and longitudinal electronic informed consent in clinical trials: How to move the needle? Digit Health, 2024 Jan 23; 10: 20552076231222361.
21. Vudathaneni VKP, Lanke RB, Mudaliyar MC, Movva KV, Mounika Kalluri L, Boyapati R. The Impact of Telemedicine and Remote Patient Monitoring on Healthcare Delivery: A Comprehensive Evaluation. Cureus, 2024 Mar 4; 16(3): e55534.
22. Telemedicine for healthcare: capabilities, features, barriers, and applications. Haleem A, Javaid M, Singh RP, Suman R. Sens Int, 2021; 2: 100117.
23. Ethan, Amelia & Md Rasel, Furqan, Ensuring Data Integrity in Clinical Trials: A Comprehensive Overview, 2023.
24. Mehrtak M, SeyedAlinaghi S, MohsseniPour M, Noori T, Karimi A, Shamsabadi A, Heydari M, Barzegary A, Mirzapour P, Soleymanzadeh M, Vahedi F, Mehraeen E, Dadras O. Security challenges and solutions using healthcare cloud computing. J Med Life, 2021 Jul-Aug; 14(4): 448-461.
25. Grady C. Institutional Review Boards: Purpose and Challenges. Chest, 2015 Nov; 148(5): 1148-1155.
26. Kim WO. Institutional review board (IRB) and ethical issues in clinical research. Korean J Anesthesiol, 2012 Jan; 62(1): 3-12.
27. Petrini C, Mannelli C, Riva L, Gainotti S, Gussoni G. Decentralized clinical trials (DCTs): A few ethical considerations. Front Public Health, 2022 Dec 15; 10: 1081150.
28. Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S. & Johnston, J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials, 2015; 16: 495.
29. Tenaerts P, Hernandez AF, Lipset C. Clinical trial site readiness for decentralized trials - fitting trials into today's world. J Clin Transl Sci, 2024 Feb 12; 8(1): e43.
30. Betcheva L, Kim JY, Erhun F, Oraiopoulos N, Getz K. Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment. Ther Innov Regul Sci., 2023 Sep; 57(5): 1081-1098.
31. Arnold RD, Wade JP. A definition of systems thinking: a systems approach. Procedia Comput Sci., 2015; 44: 669–678.
32. Serrano LP, Maita KC, Avila FR, Torres-Guzman RA, Garcia JP, Eldaly AS, Haider CR, Felton CL, Paulson MR, Maniaci MJ, Forte AJ. Benefits and Challenges of Remote Patient Monitoring as Perceived by Health Care Practitioners: A Systematic Review. Perm J., 2023 Dec 15; 27(4): 100-111.
33. Vegesna A, Tran M, Angelaccio M, Arcona S. Remote Patient Monitoring via Non-Invasive Digital Technologies: A Systematic Review. Telemed J E Health, 2017 Jan; 23(1): 3-17.
34. Olimid AP, Olimid DA. Ethical review of patient safety and public health in EU clinical trials legislation: impact of COVID-19 pandemic. Rom J Morphol Embryol, 2020; 61(1): 277-281.

35. Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci., 2020; 41(6): 363–382.
36. Park J, Huh KY, Chung WK, Yu KS. The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance. Transl Clin Pharmacol, 2024 Mar; 32(1): 41-51.
37. Reflection-paper-use-artificial-intelligence-ai-medicinal ... – EMA. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf
38. Shajari S, Kuruvinashetti K, Komeili A, Sundararaj U. The Emergence of AI-Based Wearable Sensors for Digital Health Technology: A Review. Sensors (Basel), 2023 Nov 29; 23(23): 9498.
39. Ghadanian, M., Schafheutle, E. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations. *Ther Innov Regul Sci*, 2024; 58, 79–113.
40. Comparing FDA and EMA Decisions for Market. https://www.fda.gov/media/156611/download
41. Joppi R, Bertele V, Vannini T, Garattini S, Banzi R. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval. Br J Clin Pharmacol, 2020 Jan; 86(1): 170-174.
42. Rawson NSB. Canadian, European and United States new drug approval times now relatively similar. Regul Toxicol Pharmacol, 2018; 96: 121-126.
43. Polhemus, A.M. *et al*. Accelerating adoption of patient-facing technologies in clinical trials: a pharmaceutical industry perspective on opportunities and challenges. Ther. Innov. Regul. Sci., 2019; 53: 8–24.
44. National Academies of Sciences, Engineering, and Medicine. Virtual Clinical Trials: Challenges and Opportunities: Proceedings of a Workshop (The National Academies Press, Washington, DC, 2019).
45. Gul, R.B. & Ali, P.A. Clinical trials: the challenge of recruitment and retention of participants. J. Clin. Nurs, 2010; 19: 227–233.
46. The Evolving Role of Decentralized Clinical Trials https://www.fda.gov/drugs/cder-conversations/evolving-role-decentralized-clinical-trials-and-digital-health-technologies
47. Goldstein B. A., Navar A. M., Pencina M. J., and Ioannidis J. P., "Opportunities and Challenges in Developing Risk Prediction Models With Electronic Health Records Data: A Systematic Review," Journal of the American Medical Informatics Association, 2017; 24(1): 198–208.
48. Taherdoost H. Privacy and Security of Blockchain in Healthcare: Applications, Challenges, and Future Perspectives. *Sci*., 2023; 5(4): 41.
49. Williams EL, Pierre DL, Martin ME, Beg MS, Gerber DE. Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic. JCO Oncol Pract, 2021 Sep; 17(9): 577-579.
50. Tomiwa T, Wong E, Miller HN, Ogungbe O, Byiringiro S, Plante T, Himmelfarb CR. Leveraging digital tools to enhance diversity and inclusion in clinical trial recruitment. Front Public Health, 2024 Oct 28; 12: 1483367.